Capital Markets and Philanthropy Panel at ARDD2026: What does AI in Longevity Biotech really need?

What this video covers

A video from ARDD, posted on Oct 28, 2026. It is about the science of aging.

It comes from a research institute, foundation or scientific meeting on aging. We link to it; we don't make or endorse it. Research stages on this site come from published studies, not from videos.

The science of aging: the research →

From the video's description

Panel discussion with Youssof Mal (Hevolution), Sergey Jakimov (LongeVC), Martin Borch Jensen (Gordian Biotechnology), Todd White (The Thalion Initiative), and Michelle Kwok (Draper Associates), moderated by Uli Stilz (Flagship Pioneering), at the 13th Aging Research and Drug Discovery Meeting: What does AI in Longevity Biotech really need? And how can private capital markets and philanthropy fill this gap? Key takeaway: AI alone is not a moat; investors want proprietary, human-relevant data, validated assets in specific indications and causal, longitudinal data generation. The Aging Research and Drug Discovery (ARDD) meeting is the world's leading conference dedicated to longevity biotechnology. It convenes top researchers, pharmaceutical executives, regulators, entrepreneurs, and investors to accelerate the translation of aging science into next-generation medicines. ARDD was founde…

Written by ARDD on YouTube.

More videos like this

Research instituteARDD · Oct 29, 2026Kejun (Albert) Ying at ARDD2026: An open world model for human health and mortalityThe science of agingResearch instituteARDD · Oct 29, 2026Hao Pei at ARDD2026: Aging Is Multidimensional — So Must Be the DataThe science of agingResearch instituteARDD · Oct 29, 2026Yuancheng (Ryan) Lu at ARDD2026: Functional Genomics and Virtual ScreeningThe science of agingResearch instituteARDD · Oct 27, 2026Graeme Bainbridge at ARDD2026: Feline LongevityThe science of aging